Kineta to Present at Symposium on Pandemic Preparedness
LHF-535 Lassa fever antiviral and vaccine adjuvant program to be highlighted
Seattle, WA, June 12, 2017 – Kineta, Inc., a biotechnology company focused on the development of novel immuno-therapies, today announced Kineta Vice President of R&D and Head of Virology Kristin Bedard has been invited to present at the Pandemic Preparedness for the Northwest and Beyond meeting sponsored by Life Science Washington. This Symposium will be held on June 14, 2017 from 8:30-10:30 AM PST at the Agora Conference Center in Seattle, WA.
Dr. Bedard will be joined by other leaders in infectious disease research and the global health community in discussing new approaches to developing drugs and vaccines that will address future pandemic threats. She will present an overview of Kineta’s portfolio and highlight LHF-535, Kineta’s first in class antiviral for Lassa Hemorrhagic Fever as well as the company’s vaccine adjuvant program.
This symposium will discuss threat prediction models, new medical and pharmaceutical research, the role of animals in disease outbreaks along with the roles of local measures, citizens, and businesses in helping mitigate outbreaks.
Click here to learn more about this event.
Kineta, Inc. is an emerging biotech company that fills a void in the biopharmaceutical industry by efficiently advancing first in class immuno-therapies from discovery to proof of concept. Kineta is developing a focused pipeline of novel therapies that address critical unmet patient needs in oncology, chronic pain and biodefense. We actively collaborate with a broad array of private, government, biodefense and industry partners to advance our innovative research. For more information on Kineta, Inc. visit our website, www.kinetabio.com
NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.